Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05777746
Other study ID # NL80378.041.22
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 29, 2022
Est. completion date June 2024

Study information

Verified date March 2023
Source UMC Utrecht
Contact F.L.J. Visseren, MD PhD
Phone +31 88 7555555
Email f.l.j.visseren@umcutrecht.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Persons with Type 2 Diabetes (T2D) are at an increased risk of cardiovascular disease (CVD) and mortality. Dietary changes are recommended by guidelines to treat T2D and reduce risk of CVD. Plant-based diets eliminate certain (i.e. vegetarian diet) or eliminate all animal based products (i.e. vegan diet). Clinical trials with plant-based diets have not looked at incidence of CVD as a (primary) outcome, but at intermediate outcomes of cardiovascular risk. A meta-analysis of 8 trials including 369 persons with T2D found an effect of a plant-based diet on glycated hemoglobin (HbA1c) of -0.29% [95% CI: -0.45, -0.12%] relative to mostly (omnivorous) low-fat diets or usual diet. The 95%CI ranged from what the authors had defined as clinically trivial to clinically relevant. For lipids, a network meta-analysis in persons with T2D compared the effect of a plant-based diet to a (omnivorous) low fat diet (274 patients allocated to a plant-based diet vs 2047 patients allocated to low fat diets). Compared to omnivorous low fat diets, the mean effect of plant-based diets on LDL-Cholesterol was -0.33 mmol/L [95%CI:- 0.55, - 0.12]. However, the quality of the evidence for this estimate was graded as low, mainly due to imprecision and within-study-bias. Furthermore, plant-based diets might reduce blood pressure (BP). However, while vegetarian diets reduce BP in patients with and without hypertension, for vegan diets the effect was only significant in patients with a systolic BP>130mmHgz (see section 1.4.3). Additionally, the effect of plant-based diets on inflammation, which might also be causally related to CVD risk in persons with T2D, has not been reported in trials with persons with T2D. Furthermore, most clinical trials of plant-based diets in persons with T2D have used resource intensive interventions, like weekly group meetings and cooking sessions. The effect of an online plant-based dietary intervention, which is more scalable, has not been reported in clinical trials. Lastly, factors influencing adherence in these trials have not been reported. In summary, plant-based diets likely lower CVD risk by lowering HbA1c, LDL cholesterol and potentially blood pressure in persons with T2D. However, estimated effect sizes are imprecise and the effect on inflammation is still unknown. Furthermore, trials to date have used resource intensive interventions. Thus, the present trial aims to study the effect of a primarily online plant-based dietary program on (cardio)vascular risk factors in persons with T2D. Additionally, adherence and factors influencing adherence will be investigated. Participants will be randomized to the intervention or control group. The intervention group will be guided to transition to a plant-based dietary pattern using an online platform and online sessions. Researchers will compare the intervention group to the control group, that continues with usual diet, to see if the cardiovascular risk profile of the intervention group improves.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date June 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria 1. Diagnosis of Type 2 Diabetes made by a physician 2. Using oral glucose-lowering medication and/or an insulin regime with a stable dose during at least the last two months before the screening visit; 3. Diagnosis of type 2 diabetes was made more than one year ago 4. Age of 18 years or older on the day of signing the informed consent form. 5. When the patients is also using lipid-lowering and/or blood pressure-lowering medication, than the dose should be stable for at least two months before the screening. Exclusion criteria 1. Insulin-dependent type 2 diabetes in combination with hypoglycemia unawareness. Hypoglycemia unawareness is defined as the onset of hypoglycemia before the appearance of autonomic symptoms or failure to recognize hypoglycemia. 2. Two or more episodes of severe hypoglycemia (glucose < 3 mmol/L) during the last 3 months; 3. Uncontrolled T2D, defined as a HbA1c >86 mmol/mol (>10%); 4. Uncontrolled hypertension, defined as an office systolic blood pressure = 180mmHg; 5. Inability to attend at least 60% of the scheduled meetings; 6. Pregnancy or a wish to get pregnant during the study period; 7. Diagnosis of familial hypercholesterolemia; 8. Being diagnosed with osteoporosis. 9. Known vitamin B12 deficiency, defined as serum vitamin B12 <130 pmol/L or using vitamin B12 supplements prescribed by a physician; 10. Known iron deficiency defined as a serum ferritin < 25µg/L for males or < 20µg/L for females or using iron supplements prescribed by a physician;; 11. The presence of any disease for which the patients uses a specific diet and where transitioning to a plant-based diet might lead to unfavorable effects on this disease as judged by the research team and/or the treating physician. An exception is a salt-restricted diet for hypertension; 12. Current or planned participation in any other interventional study within 30 days of signing the informed consent form; 13. Any medical, social or physiological circumstance which might interfere with the study, based on judgement by the principal investigator.

Study Design


Intervention

Behavioral:
12-week plant-based dietary program
a 12-week plant-based dietary program consisting of information via an online platform, online guidance by dieticians and in online peer support groups. Patients will aim to maximize their intake of plant-based products while reducing their of animal products as much as possible.
Usual Diet
Patients in the control group continue with their usual diet and/or usual dietary care. Patients in the control group will be offered access to the online platform at 24 weeks.

Locations

Country Name City State
Netherlands Department of Vascular Medicine UMC Utrecht Utrecht

Sponsors (1)

Lead Sponsor Collaborator
UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Subgroup analysis Subgroups will be made on the basis of baseline characteristics (e.g. age, level of education, gender, presence of hypertension, duration of T2D, use of insulin, BMI, HbA1c) Week 12 and 24
Other Effect modification by diabetes subtype and adherence to the plant-based diet Week 12 and 24
Other Determinants of adherence Patient characteristics Week 12 and 24
Other Determinants of adherence Based on outcome of the Food Choice questionnaire Week 12 and 24
Other Determinants of adherence Based on outcome of the Self-Efficacy questionnaire Week 12 and 24
Other Determinants of adherence Based on outcome of the in-group identification questionnaire Week 12 and 24
Other Effect of the 12-week online dietary program on the CVD risk profile in the control group Week 36
Other Incident Hypoglycemia Incidence of mild and severe hypoglycemia Week 12 and 24
Other Physical Activity (Metabolic Equivalent Tasks) Measured using the SQUASH questionnaire Week 12 and 24
Primary Change in HbA1c (mmol/mol) Week 12
Primary Composite of Estimated relative CVD risk (based on change in LDL-c , SBP and HbA1c) Week 12
Secondary Calculated absolute CVD risk reduction (%) Using baseline parameters (e.g. baseline LDL-C, BP, HbA1c, manifest CVD, duration of diabetes) and the risk prediction model DIAL2/SCORE-2(OP), the absolute CVD risk at baseline is calculated. The expected absolute risk reduction is calculated using changes in CVD risk profile after 12 and 24 weeks Week 12, 24 and 36
Secondary HbA1c and estimated change in absolute and relative CVD risk (based on change in LDL-c, SBP and HbA1c) Per-protocol analysis Week 12, 24 and 36
Secondary Glycemic control (HOMA2-IR, HOMA2-B%, TyG-index, NAFLD Score) Week 12 and 24
Secondary Lipids and lipoprotein profile Composition and concentration of lipoproteins and lipids, including total cholesterol, HDL-cholesterol, apolipoprotein-B, LDL-C and triglycerides Week 12 and 24
Secondary Blood pressure (systolic and diastolic) Week 12 and 24
Secondary Inflammatory profile (CRP, neutrophil and lymphocyte count) Week 12 and 24
Secondary Quality of life(EQ-5D, self-perceived stress,and DDRQOL-R(-9), medication use) Week 12 and 24
Secondary Anthropometric measurements (BMI, hip/waist ratio) Week 12, 24 and 36
Secondary Adherence (dietary index) Week 12, 24 and 36
Secondary Rate of Vitamin B12 and ferritin deficiency Week 12 and 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2

External Links